Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA.

10 Sep 2014

Researchers measure stiffness of membrane surrounding red blood cells over time

It may look like fresh blood and flow like fresh blood, but the longer blood is stored, the less it can carry oxygen into the tiny microcapillaries of the body, says a new study from University of Illinois researchers.

8 Sep 2014

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

6 Sep 2014

Scientists find that samples of chocolate purchased in Brazil contain lead and cadmium

Scientists have found that commercial samples of chocolate purchased in Brazil contain varying levels of lead and cadmium, which can cause health problems, and that those levels are linked to how much cocoa a product contains.

4 Sep 2014

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients.

30 Aug 2014

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN.

29 Aug 2014

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology.

28 Aug 2014

Penn receives orphan status in Europe for treatment of PNH

A Penn Medicine-developed drug has received orphan status in Europe this week for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis.

27 Aug 2014

Scientists find that DNA repair drug could help treat leukaemia, other cancers

A team of scientists led by Research Associate Professor Motomi Osato and Professor Yoshiaki Ito from the Cancer Science Institute of Singapore at the National University of Singapore found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukaemia and other cancers.

26 Aug 2014

Drug to kill limited type of cancer cells with DNA repair defects could treat leukaemia

A team of scientists led by Research Associate Professor Motomi Osato and Professor Yoshiaki Ito from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukaemia and other cancers.

26 Aug 2014

Aldea Pharmaceuticals announces closure of $24M Series B equity financing

Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing.

25 Aug 2014

Pregnant teenagers engaged in pica have lower iron levels

In a study of 158 pregnant teenagers in Rochester, NY, nearly half engaged in pica - the craving and intentional consumption of ice, cornstarch, vacuum dust, baby powder and soap, and other nonfood items, reports a new Cornell study.

21 Aug 2014

Regular blood transfusion therapy reduces recurrence of strokes in kids with sickle cell anemia

Vanderbilt-led research, as part of an international, multicenter trial, found regular blood transfusion therapy significantly reduces the recurrence of silent strokes and strokes in children with sickle cell anemia who have had pre-existing silent strokes, according to study results released today in the New England Journal of Medicine (NEJM).

21 Aug 2014

Research hopes to protect hundreds of newborns from severe health problems by protein in milk

An international effort led by the University of Sydney hopes to protect hundreds of Bangladeshi newborns from a host of severe health problems by assessing the effect of lactoferrin, a natural protein found in breast and cow's milk, in the treatment of iron deficiency anemia in pregnancy.

13 Aug 2014

Epigenetics has a large say in blood formation

Blood stem cells have the potential to turn into any type of blood cell, whether it be the oxygen-carrying red blood cells, or the many types of white blood cells of the immune system that help fight infection.

12 Aug 2014

Researchers find that animal's ability to endure internal parasite strongly influences reproductive success

In the first evidence that natural selection favors an individual's infection tolerance, researchers from Princeton University and the University of Edinburgh have found that an animal's ability to endure an internal parasite strongly influences its reproductive success.

8 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.

7 Aug 2014

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).

4 Aug 2014

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014